Verona Pharma plc (NASDAQ:VRNA) Given Consensus

4 days ago · Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings data on Monday, November 4th.The company reported ($0.56) earnings per share …

$0.56
OFF

Verona Pharma Plc (NASDAQ:VRNA) Given Consensus

2 weeks from now

4 days ago · Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings data on Monday, November 4th.The company reported ($0.56) earnings per share …

marketbeat.com

$42
OFF

Verona Pharma (NASDAQ:VRNA) Stock, Analyst Ratings, Price …

2 weeks from now

Verona Pharma PLC has a consensus price target of $42 based on the ratings of 7 analysts. The high is $64 issued by Wells Fargo on November 5, 2024.The low is $31 issued by BTIG on …

benzinga.com

65%
OFF

Wall Street Analysts See A 30.65% Upside In Verona Pharma

2 weeks from now

14 hours ago · Verona Pharma PLC American Depositary Share (VRNA) closed the last trading session at $46.69, gaining 9.4% over the past four weeks, but there could be plenty of upside …

nasdaq.com

65%
OFF

Wall Street Analysts See A 30.65% Upside In Verona Pharma …

2 weeks from now

1 day ago · Verona Pharma PLC American Depositary Share (VRNA Quick Quote VRNA - Free Report) closed the last trading session at $46.69, gaining 9.4% over the past four weeks, but …

zacks.com

$0.56
OFF

Verona Pharma (NASDAQ:VRNA) Earns "Buy" Rating From Truist

2 weeks from now

6 days ago · Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings results on Monday, November 4th.The company reported ($0.56) EPS for the …

marketbeat.com

$0.56
OFF

Verona Pharma (VRNA) Stock Price, News & Analysis - MarketBeat

2 weeks from now

2 days ago · Verona Pharma plc (NASDAQ:VRNA) announced its earnings results on Monday, November, 4th. The company reported ($0.56) earnings per share for the quarter, missing the …

marketbeat.com

$0.56
OFF

Verona Pharma (NASDAQ:VRNA) Upgraded To Strong-Buy At Roth …

2 weeks from now

3 days ago · Verona Pharma (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings data on Monday, November 4th.The company reported ($0.56) earnings per share …

marketbeat.com

5%
OFF

Verona Pharma (NASDAQ:VRNA) Stock Price Up 4.5% - MarketBeat

2 weeks from now

2 days ago · Verona Pharma (NASDAQ:VRNA - Get Free Report) last released its quarterly earnings results on Monday, November 4th.The company reported ($0.56) earnings per share …

marketbeat.com

65%
OFF

Wall Street Analysts See A 30.65% Upside In Verona Pharma …

2 weeks from now

Verona Pharma PLC American Depositary Share (VRNA) closed the last trading session at $46.69, gaining 9.4% over the past four weeks, but there could be plenty of upside left in the …

msn.com

FAQs about Verona Pharma plc (NASDAQ:VRNA) Given Consensus Coupon?

Is Verona Pharma a good stock to buy?

Verona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. Verona Pharma has only been the subject of 3 research reports in the past 90 days. Read more about Verona Pharma's stock forecast and price target. Elon to Transform U.S. Economy? ...

Should you buy Verona Pharma (vRNA)?

Analysts like Verona Pharma more than other "medical" companies. The consensus rating for Verona Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VRNA compares to other companies. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. ...

Will Verona Pharma breakeven in 2025?

See our latest analysis for Verona Pharma According to the 7 industry analysts covering Verona Pharma, the consensus is that breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of US$71m in 2026. The company is therefore projected to breakeven just over a year from now. ...

Who is Verona Pharma plc?

Click here now to watch this new exposé that covers it all. Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. ...

What is the price target for Verona Pharma (vRNA)?

The highest price target for VRNA is $74.00, while the lowest price target for VRNA is $33.00. The average price target represents a forecasted upside of 14.23% from the current price of $44.27. Enter your email address to receive the latest news and analysts' ratings for Verona Pharma and its competitors. ...

Is Verona Pharma plc (vRNA) approaching a major achievement?

Verona Pharma plc (NASDAQ:VRNA) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. ...